MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

MS Block; RA Vierkant; PF Rambau; SJ Winham; P Wagner; N Traficante; A Toloczko; DG Tiezzi; FA Taran; P Sinn; W Sieh; R Sharma; JH Rothstein; T Ramón y Cajal; L Paz-Ares; O Oszurek; S Orsulic; RB Ness; G Nelson; F Modugno; J Menkiszak; V McGuire; BM McCauley; M Mack; J Lubinski; TA Longacre; Z Li; J Lester; CJ Kennedy; KR Kalli; AY Jung; SE Johnatty; M Jimenez-Linan; A Jensen; MP Intermaggio; J Hung; E Herpel; BY Hernandez; AD Hartkopf; PR Harnett; P Ghatage; JM García-Bueno; B Gao; S Fereday; U Eilber; RP Edwards; CB de Sousa; JM de Andrade; A Chudecka-Glaz; G Chenevix-Trench; A Cazorla; SY Brucker; DD Bowtell; A Green; P Webb; A de Fazio; D Gertig; S Moore; K Harrap; T Sadkowsky; N Pandeya; M Malt; A Mellon; R Robertson; T Vanden Bergh; M Jones; P Mackenzie; J Maidens; K Nattress; YE Chiew; A Stenlake; H Sullivan; B Alexander; P Ashover; S Brown; T Corrish; L Green; L Jackman; K Ferguson; K Martin; A Martyn; B Ranieri; J White; V Jayde; P Mamers; L Bowes; L Galletta; D Giles; J Hendley; K Alsop; T Schmidt; H Shirley; C Ball; C Young; S Viduka; H Tran; S Bilic; L Glavinas; J Brooks; R Stuart-Harris

Journal article

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

MS Block, RA Vierkant, PF Rambau, SJ Winham, P Wagner, N Traficante, A Toloczko, DG Tiezzi, FA Taran, P Sinn, W Sieh, R Sharma, JH Rothstein, T Ramón y Cajal, L Paz-Ares, O Oszurek, S Orsulic, RB Ness, G Nelson, F Modugno Show all

Mayo Clinic Proceedings | ELSEVIER SCIENCE INC | Published : 2018

DOI: 10.1016/j.mayocp.2017.10.023

Download PDF

Abstract

Objective: To evaluate myeloid differentiation primary response gene 88 (MyD88) and Toll-like receptor 4 (TLR4) expression in relation to clinical features of epithelial ovarian cancer, histologic subtypes, and overall survival. Patients and Methods: We conducted centralized immunohistochemical staining, semi-quantitative scoring, and survival analysis in 5263 patients participating in the Ovarian Tumor Tissue Analysis consortium. Patients were diagnosed between January 1, 1978, and December 31, 2014, including 2865 high-grade serous ovarian carcinomas (HGSOCs), with more than 12,000 person-years of follow-up time. Tissue microarrays were stained for MyD88 and TLR4, and staining intensity wa..

View full abstract

University of Melbourne Researchers

Nadia Traficante Author

Julie Fereday Author

Ian Campbell Author

Kathryn Alsop Author

Related Projects (5)

Molecular Epidemiology of Ovarian Research Institute

PUBLIC ABSTRACT A major obstacle to preventive strategies for ovarian cancer is the lack of recognized modifiable risk factors. Age, a pos..

Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core

Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 ne..

AUSTRALASIAN BIOSPECIMEN NETWORK-ONCOLOGY

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

Australian Biospecimen Network-Oncology

Availability of ethically consented, clinically annotated human cancer tissue is a key determinant of the international competitiveness of A..

Grants

Awarded by Calgary Laboratory Services

Funding Acknowledgements

The work was supported by grant MOP-86727 from the Canadian Institutes for Health Research; grant 478416/2009-1 from the Brazilian National Council for Scientific and Technological Development; grant RS10-533 from the Calgary Laboratory Services Internal Research Competition; grant 01 GB 9401 from the German Federal Ministry of Education and Research of Germany; grants from the German Cancer Research Center (Deutsches Krebsforschungszentrum); grants K07-CA80668, P50-CA159981, and R01CA095023 from the US National Cancer Institute; grant MO1-RR000056 from the National Institutes of Health (NIH)/National Center for Research Resources/General Clinical Research Center; grant DAMD17-02-1-0669 from the US Army Medical Research and Materiel Command; grants R01-CA122443, P50-CA136393, P30-CA15083, U01-CA71966, U01-CA69417, R01-CA16056, and K07-CA143047 from the NIH; grants C490/A10119, C490/A10123, and C490/A16561 from Cancer Research UK; grants from the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge and at University College Hospital "Womens Health Theme"; grant SFB 685 from the NIH; grants from the Eve Appeal; grants from the Oak Foundation; grants from Deutsche Forschungsgemeinschaft; grant DAMD17-01-1-0729 (A.O.C.S.) from the US Army Medical Research and Material Command; grants from the Cancer Council Victoria; grants from Queensland Cancer Fund; grants from the Cancer Council New South Wales; grants from the Cancer Council South Australia; grants from the Cancer Foundation of Western Australia; grants from the Cancer Council Tasmania; grants ID400413 and ID400281 from the National Health and Medical Research Council of Australia; grants from the Peter MacCallum Cancer Foundation and Ovarian Cancer Australia (A.O.C.S); enabling grants ID 310670 and ID 628903 (the Gynaecological Oncology Biobank at Westmead, a member of the Australasian Biospecimen Network Oncology group) from the National Health and Medical Research Council; grants 12/RIG/1-17 and 15/RIG/1-16 from the Cancer Institute NSW (the Gynaecological Oncology Biobank at Westmead, a member of the Australasian Biospecimen Network-Oncology group); research grant R01-CA61107 (Malignant Ovarian Cancer Study) from the National Cancer Institute, Bethesda, MD; research grant 94 222 52 (MALOVA) from the Danish Cancer Society, Copenhagen, Denmark, and a grant (Malignant Ovarian Cancer Study) from the Mermaid I project; grant 15/TRC/101 (A.F. and P.R.H.) from the Cancer Institute NSW; grant SIOP-06-258-01-COUN (B.Y.K.) from the American Cancer Society Early Detection Professorship; and grant UL1TR000124 from the National Center for Advancing Translational Sciences (B.Y.K.).